
    
      This study plans to enroll 25 patients to assess the safety and efficacy of EXP039. Subjects
      who meet the eligibility criteria will receive a single dose of EXP039 injection.

      The study will include the following sequential phases: Screening, Pre-treatment (Cell
      product preparation; Lymphodepleting Chemotherapy), Treatment and follow-up.
    
  